V1RD17 Inhibitors
V1RD17 inhibitors are a class of chemical compounds that interact with a specific biochemical pathway by targeting a molecule known as V1RD17. This molecule plays a crucial role in a particular biological process, and the inhibitors are designed to bind to V1RD17 and alter its normal function. The action of these inhibitors hinges on their ability to fit into the active site or another significant binding region of the V1RD17 molecule, which leads to the modulation of its activity. This modulation can either increase or decrease the activity of the V1RD17, depending on the nature of the inhibitor and the specific context of its interaction with the molecular target.
The structure of V1RD17 inhibitors is often complex, owing to the need for a high degree of specificity in their interaction with V1RD17. The design of these compounds takes into account the three-dimensional shape of the V1RD17 molecule, as well as the electronic and chemical properties of its active site. This often involves a detailed understanding of the biochemistry involved in the V1RD17 pathway, including the types of bonds that can be formed or broken and the steric considerations that dictate how the inhibitor can approach and interact with V1RD17. The development of V1RD17 inhibitors typically requires a multi-disciplinary approach that includes elements of organic chemistry, molecular biology, computational modeling, and various types of spectroscopy and crystallography to determine the structure of the target molecule and the best way to influence its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A specific inhibitor of the vacuolar-type H+-ATPase that disrupts proton gradients across intracellular organelles. In cells expressing V1RD17, this disruption might impede endocytic recycling or degradation pathways that V1RD17 requires for proper signaling, leading to decreased protein function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of many signaling pathways, including those potentially involving V1RD17. By inhibiting PI3K, LY294002 can prevent the activation of downstream effectors that might be necessary for V1RD17-mediated signal transduction. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. If V1RD17 signaling is reliant on the MAPK/ERK pathway, U0126-mediated inhibition would prevent its activation, thereby leading to a reduction in V1RD17's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An inhibitor of mTOR (mechanistic target of rapamycin), which plays a central role in cellular growth and metabolism. Rapamycin could diminish V1RD17 activity if the protein's function is associated with pathways regulated by mTOR, such as protein synthesis or autophagy. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad-spectrum protein kinase C (PKC) inhibitor. If V1RD17's function is mediated through a PKC-dependent pathway, Go 6983 would lead to a decrease in V1RD17 signaling by inhibiting PKC activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which blocks the activation of MAPK/ERK kinase. If V1RD17 operates within this pathway, PD98059 would result in reduced V1RD17 activity by preventing the phosphorylation and activation of MAPK/ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. Inhibition of p38 MAP kinase could result in decreased V1RD17 function if V1RD17 relies on the p38 MAPK pathway for its activity. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A selective inhibitor of NUAK family SNF1-like kinase 1 (NUAK1). If V1RD17's function is NUAK1-dependent, WZ4003 would lead to decreased activity of V1RD17 by blocking NUAK1-mediated signaling. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
An inhibitor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. If V1RD17's activity is linked to NF-κB pathway activation, JSH-23 would result in decreased V1RD17 function by blocking NF-κB translocation to the nucleus and subsequent transcriptional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK could lead to decreased V1RD17 function if V1RD17 is part of JNK signaling pathways involved in stress response, apoptosis, or other cellular processes. | ||||||